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PREAMBLE
This document was developed by a consensus conference
initiated by Kristian Thygesen, MD, and Joseph S. Alpert,
MD, after formal approval by Lars Ryde´n, MD, President
of the European Society of Cardiology (ESC), and Arthur
Garson, MD, President of the American College of Cardi-
ology (ACC). All of the participants were selected for their
expertise in the field they represented, with approximately
one-half of the participants selected from each organization.
Participants were instructed to review the scientific evidence
in their area of expertise and to attend the consensus
conference with prepared remarks. The first draft of the
document was prepared during the consensus conference
itself. Sources of funding appear in Appendix A. The
recommendations made in this document represent the
attitudes and opinions of the participants at the time of the
conference, and these recommendations were revised sub-
sequently. The conclusions reached will undoubtedly need
to be revised as new scientific evidence becomes available.
This document has been reviewed by members of the ESC
Committee for Scientific and Clinical Initiatives and by
members of the Board of the ESC who approved the
document on April 15, 2000.*
I. INTRODUCTION: CONCEPT AND
DEFINITION OF MYOCARDIAL INFARCTION
Myocardial infarction (MI) can be defined from a number
of different perspectives related to clinical, electrocardio-
graphic (ECG), biochemical and pathologic characteristics.
The term MI also has social and psychological implications,
both as an indicator of a major health problem and as a
measure of disease prevalence in population statistics and
outcomes of clinical trials (Fig. 1).
In the distant past, a general consensus existed for the
clinical entity designated as MI. In studies of disease
prevalence by the World Health Organization (WHO), MI
was defined by a combination of two of three characteristics:
typical symptoms (i.e., chest discomfort), enzyme rise and a
typical ECG pattern involving the development of Q waves.
However, current clinical practice, health care delivery
systems, as well as epidemiologic studies and clinical trials,
all require a more precise definition of MI. Furthermore, the
advent of sensitive and specific serologic biomarkers and
*The recommendations set forth in this report are those of the conference
participants and do not necessarily reflect the official position of the American College
of Cardiology. The full text of the document will be published simultaneously in the
European Heart Journal and the Journal of the American College of Cardiology. This
document is available on the World Wide Web sites of the American College of
Cardiology (www.acc.org) and the European Society of Cardiology (www.esc.org).
Reprints of this document are available for $5.00 each by calling 800-253-4636 (U.S.
only) or by writing the Resource Center, American College of Cardiology, 9111 Old
Georgetown Road, Bethesda, Maryland 20814.
**A list of contributors to this ESC/ACC Consensus Document is provided in
Appendix B.
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precise imaging techniques necessitate reevaluation of es-
tablished definitions of MI. The latter technologic advances
have high sensitivity to detect very small infarcts that would
not have been considered an MI in an earlier era. Current
technology can identify patients with small areas of myo-
cardial necrosis weighing ,1.0 g. Thus, if we accept the
concept that any amount of myocardial necrosis caused by
ischemia should be labeled as an infarct (as proposed by this
consensus conference), then an individual who was formerly
diagnosed as having severe, stable or unstable angina pec-
toris might be diagnosed today as having had a small MI.
The resulting increase in the sensitivity of the defining
criteria for MI would mean more cases identified; in
contrast, an increase in specificity would lessen the number
of false positive MIs. Such changes in definition might have
a profound effect on the traditional monitoring of disease
rates and outcomes.
In response to the issues posed by an alteration in our
ability to identify MI, the ESC and the ACC convened a
consensus conference during July 1999 to reexamine jointly
the definition of MI. The scientific and societal implications
of a new definition for MI were examined from seven points
of view: pathology, biochemistry, electrocardiography, im-
aging, clinical trials, epidemiology and public policy. It
became apparent from the deliberations of the consensus
committee that the term MI should not be used without
further qualifications, whether in clinical practice, in the
description of patient cohorts or in population studies. Such
qualifications should refer to the amount of myocardial cell
loss (infarct size), to the circumstances leading to the infarct
(spontaneous or in the setting of a coronary artery diagnostic
or therapeutic procedure) and to the timing of the myocar-
dial necrosis relative to the time of the observation (evolv-
ing, healing or healed MI).
II. CLINICAL PRESENTATION
It is accepted that the term MI reflects a loss of cardiac
myocytes (necrosis) caused by prolonged ischemia. Ischemia
is the result of a perfusion-dependent imbalance between
supply and demand. Ischemia in a clinical setting can be
identified from the patient’s history and from the ECG.
Possible ischemic symptoms include chest, epigastric, arm,
wrist or jaw discomfort with exertion or at rest. The
discomfort associated with acute MI usually lasts at least
20 min, but may be shorter in duration. The discomfort may
develop in the central or left chest and then radiate to the
arm, jaw, back or shoulder. The discomfort is usually not
sharp or highly localized and may be associated with
dyspnea, diaphoresis, nausea, vomiting or light-headedness.
The discomfort can develop in the epigastrium (often
confused with indigestion), arm, shoulder, wrist, jaw or
back, without occurring in the chest, but such a pattern is
atypical. The discomfort is not affected by moving the
muscles of the region where the discomfort is localized, nor
is it worsened by deep inspiration. The discomfort is not
positional in nature. Symptoms can also include unex-
plained nausea and vomiting, persistent shortness of breath
secondary to left ventricular failure and unexplained weak-
ness, dizziness, lightheadedness or syncope, or a combina-
tion of these. These symptoms may be noted in association
with chest discomfort or they may occur in the absence of
chest symptoms.
Although many patients have symptoms such as those
just described, these complaints may go unrecognized or
may be erroneously labeled as another disease entity, such as
indigestion or a viral syndrome. Myocardial necrosis may
also occur without symptoms; it may be detected only by the
ECG, cardiac imaging or other studies.
III. DETECTION OF NECROSIS OF MYOCARDIAL CELLS
The presence or absence and the amount of myocardial
damage resulting from prolonged ischemia can be assessed
by a number of different means, including pathologic
examination, measurement of myocardial proteins in the
blood, ECG recordings (ST-T segment wave changes, Q
waves), imaging modalities such as myocardial perfusion
imaging, echocardiography and contrast ventriculography.
For each of these techniques, a gradient can be distin-
guished from minimal to small to large amounts of myo-
cardial necrosis. Some clinicians classify myocardial necrosis
as microscopic, small, moderate and large on the basis of the
peak level of a particular biomarker. The sensitivity and
specificity of each of these techniques used to detect
myocardial cell loss, quantitate this loss and recognize the
sequence of events over time, differ markedly (Table 1).
1. Pathology. Myocardial infarction is defined as myocardial
cell death due to prolonged ischemia. Cell death is catego-
rized pathologically as either coagulation or contraction
band necrosis, or both, which usually evolves through
oncosis, but can result to a lesser degree from apoptosis.
Careful analysis of histologic sections by an experienced
observer is essential to distinguish these entities.
After the onset of myocardial ischemia, cell death is not
immediate but takes a finite period to develop (as little as
15 min in some animal models, but even this may be an
overestimate). It takes 6 h before myocardial necrosis can be
identified by standard macroscopic or microscopic postmor-
tem examination. Complete necrosis of all myocardial cells
at risk requires at least 4 h to 6 h or longer, depending on
the presence of collateral blood flow into the ischemic zone,
Table 1. Aspects of MI by Different Techniques
Pathology Myocardial cell death
Biochemistry Markers of myocardial cell death
recovered from blood samples
Electrocardiography Evidence of myocardial ischemia
(ST-T segment changes)
Evidence of loss of electrically
functioning cardiac tissue (Q waves)
Imaging Reduction or loss of tissue perfusion
Cardiac wall motion abnormalities
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persistent or intermittent coronary artery occlusion and the
sensitivity of the myocytes.
Infarcts are usually classified by size—microscopic (focal
necrosis), small (,10% of the left ventricle), medium (10%
to 30% of the left ventricle) or large (.30% of the left
ventricle)—as well as by location (anterior, lateral, inferior,
posterior or septal or a combination of locations). The
pathologic identification of myocardial necrosis is made
without reference to morphologic changes in the epicardial
coronary artery tree or to the clinical history.
The term MI in a pathologic context should be preceded
by the words “acute, healing or healed.” An acute or
evolving infarction is characterized by the presence of
polymorphonuclear leukocytes. If the interval between the
onset of infarction and death is brief (e.g., 6 h), minimal or
no polymorphonuclear leukocytes may be seen. The pres-
ence of mononuclear cells and fibroblasts and the absence of
polymorphonuclear leukocytes characterize a healing infarc-
tion. A healed infarction is manifested as scar tissue without
cellular infiltration. The entire process leading to a healed
infarction usually requires five to six weeks or more. Fur-
thermore, reperfusion alters the gross and microscopic
appearance of the necrotic zone by producing myocytes with
contraction bands and large quantities of extravasated eryth-
rocytes.
Infarcts are classified temporally according to the patho-
logic appearance as follows: acute (6 h to 7 days); healing (7
to 28 days), healed (29 days or more). It should be
emphasized that the clinical and ECG timing of an acute
ischemic event may not be the same as the pathologic
timing of an acute infarction. For example, the ECG may
still demonstrate evolving ST-T segment changes, and
cardiac troponin may still be elevated (implying a recent
infarct) at a time when, pathologically, the infarct is in the
healing phase.
2. Biochemical markers of myocardial necrosis. Myocar-
dial necrosis results in and can be recognized by the
appearance in the blood of different proteins released into
the circulation due to the damaged myocytes: myoglobin,
cardiac troponins T and I, creatine kinase, lactate dehydro-
genase, as well as many others (Fig. 2). Myocardial infarc-
tion is diagnosed when blood levels of sensitive and specific
biomarkers, such as cardiac troponin and the MB fraction of
creatine kinase (CK-MB), are increased in the clinical
setting of acute ischemia. These biomarkers reflect myocar-
dial damage but do not indicate its mechanism. Thus, an
elevated value in the absence of clinical evidence of ischemia
should prompt a search for other causes of cardiac damage,
such as myocarditis.
The most recently described and preferred biomarker for
myocardial damage is cardiac troponin (I or T), which has
nearly absolute myocardial tissue specificity, as well as high
sensitivity, thereby reflecting even microscopic zones of
myocardial necrosis. An increased value for cardiac troponin
should be defined as a measurement exceeding the 99th
percentile of a reference control group. Reference values
must be determined in each laboratory by studies using
specific assays with appropriate quality control, as reported
in peer-reviewed journals. Acceptable imprecision (coeffi-
cient of variation) at the 99th percentile for each assay
should be defined as #10%. Each individual laboratory
should confirm the range of reference values in their specific
setting. In addition, meticulous laboratory practice must be
maintained. Because cardiac troponin values may remain
elevated for 7 to 10 days or longer after myocardial necrosis,
care should be exercised in attribution of elevated cardiac
troponin levels to very recent clinical events (Table 2).
If cardiac troponin assays are not available, the best
alternative is CK-MB (measured by mass assay). This is less
tissue-specific than cardiac troponin, but the data docu-
menting its clinical specificity for irreversible injury are more
robust. As with cardiac troponin, an increased CK-MB
value (i.e., above the decision limit for MI) is defined as one
that exceeds the 99th percentile of CK-MB values in a
reference control group. In most situations, elevated values
for biomarkers should be recorded from two successive
blood samples to diagnose MI.
Measurement of total CK is not recommended for the
routine diagnosis of acute MI, because of the wide tissue
distribution of this enzyme. Nevertheless, total CK has a
long history, and some physicians may opt to continue to
employ it for epidemiologic or scientific purposes. In such a
setting, total CK should be combined with a more sensitive
biomarker, such as cardiac troponin or CK-MB, for more
accurate clinical diagnosis of acute MI. The cut-off limits
for total CK should be relatively higher than those for
cardiac troponin or CK-MB (at least twice the upper
reference limit for CK). Glutamic-oxaloacetic transaminase
(ASAT [aspartate amino transferase]), lactate dehydroge-
nase and lactate dehydrogenase isoenzymes should not be
used to diagnose cardiac damage. Along with other clinical
factors (e.g., residual left ventricular function), the degree of
biomarker elevation is related to clinical risk. A classification
for the extent of myocardial damage (microscopic, small,
Table 2. Biochemical Markers for Detecting Myocardial Necrosis
The following are biochemical indicators for detecting myocardial necrosis: 1) Maximal concentration of troponin T or I exceeding the decision limit
(99th percentile of the values for a reference control group) on at least one occasion during the first 24 h after the index clinical event, 2) Maximal
value of CK-MB (preferably CK-MB mass) exceeding the 99th percentile of the values for a reference control group on two successive samples, or
maximal value exceeding twice the upper limit of normal for the specific institution on one occasion during the first hours after the index clinical
event. Values for CK-MB should rise and fall; values that remain elevated without change are almost never due to MI. In the absence of availability
of a troponin or CK-MB assay, total CK (greater than two times the upper reference limit) or the B fraction of CK may be employed, but these
last two biomarkers are considerably less satisfactory than CK-MB.
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medium or large) should be employed, although no gener-
ally accepted grading system of infarct size exists.
For most patients, blood should be obtained for testing
on hospital admission, at 6 to 9 h and again at 12 to 24 h if
the earlier samples are negative and the clinical index of
suspicion is high. For patients in need of an early diagnosis,
a rapidly appearing biomarker (such as CK-MB isoforms or
myoglobin), plus a biomarker that rises later (e.g., cardiac
troponin), is recommended for confirmation of the diagno-
sis (Fig. 1).
Detection of reinfarction is clinically important because it
carries incremental risk for the patient. Reinfarction may
present special diagnostic difficulties, because an increase of
cardiac troponin can be long-lasting, and when cardiac
troponin is persistently high, the timing of the initial
myocardial damage is difficult to ascertain. If the first
sample on presentation has a high cardiac troponin value,
then sequential samples of a biomarker with a shorter time
course, such as CK-MB or myoglobin, could be employed
to clarify the timing of the infarct.
3. Electrocardiography. The ECG may show signs of
myocardial ischemia, specifically ST segment and T wave
changes, as well as signs of myocardial necrosis, specifically
changes in the QRS pattern. A working definition for acute
or evolving MI in the presence of a clinically appropriate
syndrome, as demonstrated by standard 12-lead ECG, has
been established by using data from clinical and pathoanatomic
correlative studies. The following ECG criteria (in the absence
of QRS confounders [i.e., bundle branch block, left ventricular
hypertrophy, Wolff-Parkinson-White syndrome]) have
emerged as robust determinants for the diagnosis of myocardial
ischemia (Table 3). Such ischemic changes may be associated
with evolving MI, as discussed subsequently (Fig. 1).
The ECG criteria in Table 3 reflect myocardial ischemia
and are not sufficient by themselves to define MI. The final
diagnosis of myocardial necrosis depends on the detection of
elevated levels of cardiac biomarkers in the blood, as
discussed earlier. ST segment elevation in patients with
suspected acute MI can resolve rapidly either spontaneously
or after therapy. The effect of reperfusion therapy on ST
segment changes should be taken into consideration when
using the ECG to diagnose MI. Some patients with rapid
reversal of ST segment elevation will not develop myocar-
dial necrosis. Moreover, ST segment depression, which is
maximal in leads V1 through V3, without ST segment
elevation in other leads, should be considered as indicative
of posterior ischemia or infarction, or both, but imaging
studies are usually needed to confirm the presence of
ischemia or infarction in an individual patient. In the
presence of new or presumed new left bundle branch block,
ST segment elevation can accompany the bundle branch
block, making it difficult or impossible to recognize an acute
Figure 1. Clinical classification of acute coronary syndromes.
NQMI 5 non-Q wave myocardial infarction; NSTEMI 5 non-ST elevation myocardial infarction; Q wave MI 5 Q wave myocardial infarction; ST
5 ST segment of ECG tracing.
Table 3. ECG Changes Indicative of Myocardial Ischemia That
May Progress to MI
1. Patients with ST segment elevation:
New or presumed new ST segment elevation at the J point in two or
more contiguous leads with the cut-off points $0.2 mV in leads V1,
V2, or V3 and $0.1 mV in other leads (contiguity in the frontal
plane is defined by the lead sequence aVL, I, inverted aVR, II, aVF,
III).
2. Patients without ST segment elevation:
a. ST segment depression
b. T wave abnormalities only
New or presumed new ST segment depression or T wave abnormalities, or both,
should be observed in two or more contiguous leads. Also, new or presumed new
symmetric inversion of T waves $1 mm should be present in at least two contiguous
leads.
Table 4. Electrocardiographic Changes in Established MI
1. Any Q wave in leads V1 through V3, Q wave . or 5 to 30 ms (0.03
s) in leads I, II, aVL, aVF, V4, V5, or V6. (The Q wave changes
must be present in any two contiguous leads, and be . or 5 to 1
mm in depth.)
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infarction, and criteria indicative of acute MI need to be
defined by further research. Tall and peaked T waves
(hyperacute T waves) have been noted during the very early
phases of acute MI.
New or presumed new ST segment depression or T wave
abnormalities, or both, should be observed in two or more
contiguous leads on two consecutive ECGs at least several
hours apart.
Myocardial necrosis or clinically established MI may be
defined from standard 12-lead ECG criteria in the absence
of QRS confounders (e.g., bundle branch block, left ven-
tricular hypertrophy, Wolff-Parkinson-White syndrome) or
immediately after coronary artery bypass graft surgery,
utilizing the QRS changes presented in Table 4. A single
ECG that meets the Q wave criteria in Table 4 is indicative
of a previous MI. Q waves ,30 ms in duration associated
with ST-T segment depression may represent infarction,
but these findings require more research and confirmation.
When three or more ECG recordings are obtained, then at
least two consecutive ECGs should demonstrate the abnor-
mality in question. Criteria for Q wave depth require more
research, as do QRS criteria to establish the diagnosis of
posterior MI. Bundle branch block with additional Q waves
is included in these descriptions. Right bundle branch block
will not interfere with the ability to diagnose Q waves; left
bundle branch block usually obscures Q waves; new Q waves
in the presence of left bundle branch block should be
considered as pathologic.
Not all patients who develop myocardial necrosis exhibit
ECG changes. Thus, a normal ECG does not rule out the
diagnosis of MI. Since new sensitive biochemical markers
enable detection of myocardial necrosis too small to be
associated with QRS abnormalities, some patients will have
their peak values in the subrange of any QRS changes. Such
patients might be considered to have only a microinfarction,
but these aspects need further clarification.
4. Imaging. Imaging techniques have been used to assist in
1) ruling out or confirming the presence of acute infarction
or ischemia in the Emergency Department; 2) identifying
nonischemic conditions causing chest pain; 3) defining
short- and long-term prognoses; and 4) identifying me-
chanical complications of acute infarction. The rationale of
acute imaging using echocardiographic or nuclear tech-
niques in patients suspected of having acute ischemia is that
ischemia results in regional myocardial hypoperfusion, lead-
ing to a cascade of events that can include myocardial
dysfunction and ultimately cell death. Only conventional
methods such as cross-sectional echocardiography, radionu-
clide angiography and myocardial single-photon emission
computed tomographic (SPECT) perfusion imaging are
discussed in this document, and not those that are presently
being tested in clinical research studies.
One of the major advantages of echocardiography is that
it allows assessment of most nonischemic causes of acute
chest pain, such as perimyocarditis, valvular heart disease
(aortic stenosis), pulmonary embolism and aortopathies
(aortic dissection).
Radionuclide techniques enable the physician to assess
perfusion at the time of patient presentation; this can be
performed with immediate tracer injection, because image
acquisition can be delayed for 60 to 90 min. Quantitative
analysis is an advantage of this technique. The accuracy of
the studies is high when interpreted by skilled observers.
These studies also provide simultaneous information on
myocardial perfusion and function.
Biomarkers are more sensitive, more specific and less
costly than imaging techniques for the diagnosis of myo-
cardial necrosis. Injury involving .20% of myocardial wall
thickness is required before a segmental wall motion abnor-
mality can be detected by echocardiography. In general,
.10 g of myocardial tissue must be injured before a
radionuclide perfusion defect can be resolved. Neither
technique can distinguish ischemia from infarction.
a) Acute ischemia and acute or evolving MI. By its ability to
detect regional wall motion abnormalities within minutes of
an ischemic injury, two-dimensional echocardiography may
be useful in the diagnosis of acute MI. Both the localization
and extent of infarction can be determined. An echocardio-
graphic or radionuclide image early after the onset of
symptoms is of great help in the assessment of patients with
suspected acute MI and a nondiagnostic or noninterpretable
ECG. With acute imaging in such patients, a normal
echocardiogram or a normal rest gated technetium-99m
SPECT study is useful for excluding acute infarction,
because of a 95% to 98% negative predictive value when
CK-MB is used as the gold standard. However, it is
unknown whether these techniques have the same negative
predictive value in patients with elevated troponin and a
normal CK-MB value.
A wall motion abnormality on echocardiographic or
radionuclide imaging may be caused by acute MI or one of
a number of several myocardial ischemic conditions, includ-
ing an old MI, acute ischemia, stunning or hibernation, or
a combination. The positive predictive value of echocardi-
ography is ;50% for the diagnosis of acute MI, because of
the aforementioned conditions and other non–infarct-
related etiologies of wall motion abnormalities (e.g., dilated
cardiomyopathy). The positive predictive value for gated
SPECT is also limited, because abnormal regional perfusion
and/or an old MI, acute ischemia, stunning and/or hiber-
nation may cause regional dysfunction. Attenuation artifacts
and inexperienced interpreters may also lead to false positive
scan interpretation.
b) Established MI. Echocardiography is useful after a
sudden event for analysis of residual left ventricular func-
tion. Determination of left ventricular function has prog-
nostic value. Left ventricular function can be evaluated
during exercise or dobutamine stress; the results of such
testing conveys information on myocardial viability. The
number of segments involved allows one to calculate a wall
motion score as a measure of residual left ventricular
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function, which has early and late prognostic value in
predicting complications and survival. Coexisting mitral
valve dysfunction, infarct expansion, mural thrombus and
mechanical complications of infarction are easily identified.
Echocardiography is the diagnostic procedure of choice for
identification of mechanical complications of MI.
Radionuclide techniques can also be used in the healing
or healed phases of infarction for prognostication. In con-
junction with exercise or vasodilator stress, measuring the
extent of defect reversibility can identify the extent of
ischemia. Detecting defects in more than one coronary
artery zone can identify multivessel disease. A variety of
prognostic findings can be identified (e.g., lung uptake of
the tracer thallium-201, ischemic left ventricular cavity
dilation, defect size that corresponds to infarct size). Finally,
the extent of myocardial viability can be estimated by
quantitative perfusion imaging with either thallium-201 or
technetium-99m perfusion tracers.
IV. MI IN SPECIFIC CLINICAL SETTINGS
1. Percutaneous coronary artery intervention. An in-
crease of cardiac biomarkers after coronary angioplasty or
implantation of coronary artery stents, or both, is indicative
of cell death. Because this necrosis occurs as a result of
myocardial ischemia, it should be labeled as an MI accord-
ing to the new criteria. Large infarcts in this setting may be
caused by a complicated procedure and can usually be
recognized clinically. In contrast, small or tiny infarcts are
more frequent and are probably the result of microemboli
from the atherosclerotic lesion that has been disrupted
during angioplasty or from the particulate thrombus at the
site of the culprit lesion.
In the setting of percutaneous coronary artery interven-
tions, small infarcts may, and should, be detected by serial
blood sampling and analysis before and after the procedure
(6 to 8 h and 24 h, respectively). The peak level of the
myocardial biomarkers may be pronounced and of relatively
greater magnitude because of the reperfusion associated
with the procedure. Myocardial cell injury occurring after
angioplasty may be a one-time event, as compared with the
often repetitive nature of spontaneously occurring episodes
of myocardial ischemia and necrosis. However, it is likely
that patients who develop a coronary embolism and small
infarcts have atherosclerotic lesions that are apparently
unstable, and hence represent a subgroup at risk for future
events. Indeed, it has been convincingly demonstrated that
the risk of subsequent ischemic heart disease events (death
or MI) is related to the extent of cardiac troponin or
CK-MB increase, and the prognosis for these individuals is
usually worse than that for patients who do not develop
these small increases in biomarkers after interventional
procedures. Accordingly, patients with elevated biomarkers
after an otherwise uncomplicated procedure may require
particularly careful instructions to respond appropriately to
recurrent symptoms.
2. Cardiac surgery. Myocardial damage in association with
cardiac surgery can be caused by different mechanisms,
including direct trauma by sewing needles; focal trauma
from surgical manipulation of the heart; global ischemia
from inadequate perfusion, myocardial cell protection or
anoxia; coronary artery or venous graft embolism; and other
complications of the procedure. A portion of this damage
may be unavoidable. Moreover, no biomarker is capable of
distinguishing damage due to an acute infarction from the
usually small quantity of myocardial cell damage associated
with the procedure itself. Nevertheless, the higher the value
for the cardiac biomarker after the procedure, the greater the
amount of damage to the myocardium, irrespective of the
mechanism of injury.
V. IMPLICATIONS OF DIFFERENT DEFINITIONS OF MI
The recent introduction of cardiac troponins T and I into
routine daily clinical practice allows for highly accurate,
sensitive and specific determination of myocardial injury. In
the setting of myocardial ischemia, it is now possible to
define infarcts of minimal size as well as larger infarcts. It is
now clear that any amount of myocardial damage, as
detected by cardiac troponins, implies an impaired clinical
outcome for the patient. This is apparently true for individ-
uals with spontaneous events, as well as for patients who
undergo coronary artery interventions. A review of currently
available data demonstrates no discernible threshold below
which an elevated value for cardiac troponin would be
deemed harmless. All elevated values are associated with a
worsened prognosis. It should be emphasized that there is a
continuous relation between minimal myocardial damage,
characterized by elevation of cardiac troponin without
elevation of other cardiac biomarkers (e.g., CK-MB) and
large infarcts, characterized by complications such as heart
failure or shock. Thus, any amount of myocardial necrosis
caused by ischemia should be labeled as MI. Additional
descriptors are needed to describe the state of residual left
ventricular function, the extent and severity of coronary
artery disease and the stability or instability of the patient’s
clinical course.
1. Epidemiology. Monitoring of cardiovascular disease in a
population is of utmost importance, because it enables the
investigator to analyze possible causal factors and to assess
the effect of various preventive measures, such as changes in
diet or life-style, as well as the effect of medications. The
incidence of a new MI and the prevalence of established
infarcts represent important epidemiologic variables. The
application of the new, more sensitive diagnostic criteria for
MI will cause the recorded incidence of MI to rise and the
case fatality rate to fall. Thus, a new definition of MI will
confuse efforts to follow trends in disease rates and out-
comes that are now being used to monitor the impact of
public health measures and treatments. However, this
would not be a valid reason to hold onto old definitions of
MI which no longer reflect current scientific thinking. In
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fact, changes in definitions have already occurred, albeit
unnoticed—for example, through substitution of newer
biomarkers (CK-MB, troponin) for older ones (ASAT,
CK). Continued tracking of these trends will require meth-
ods for adjusting the new criteria to the old; for example,
specific surveillance centers will be needed to measure total
CK and CK-MB, together with the newer biomarkers.
Established definitions of MI (e.g., Minnesota code,
WHO MONICA) should be retained by specific epidemi-
ologic centers for comparison with previously collected data.
At the same time, these centers should use the current
biomarker-based definition of acute MI to compare earlier
data with subsequent data collected at research centers
employing more recent standards for defining acute MI.
2. Clinical trials. Myocardial infarction can be used either
as an entry criterion or as an end point in a clinical trial.
Entry criteria in clinical investigations dealing with sus-
pected acute or evolving MI or unstable angina reflect the
initial working diagnosis at the time the patient is enrolled
in the trial. This will not necessarily correspond to the final
diagnosis of MI, because spontaneous or therapeutically
induced changes may alter the likelihood of developing
myocardial necrosis. Usually, a combination of chest dis-
comfort of a determined length of time and ECG abnor-
malities (ST segment elevation or a new bundle branch
block) is required for the initial working diagnosis of MI.
Trials of long-term management may require a definite or
hospital discharge diagnosis of MI, usually on the basis of
ECG Q waves and biochemical markers. Independent of
the precise entry criteria chosen, the randomization process
will ensure balanced groups of patients for comparison of
different treatment modalities. Modification of the defini-
tion of MI may impact patient selection or the generaliz-
ability of the trial outcome, or both.
In many trials of MI or unstable angina, as well as of
primary and secondary prevention of coronary heart disease
events, MI is one of the trial end points, usually in
combination with total mortality or cardiovascular mortal-
ity. In recent trials, different definitions of MI as an end
point have been employed, thereby hampering comparison
of trial results and meta-analyses.
Myocardial damage may occur in different clinical set-
tings: spontaneous, during percutaneous intervention, dur-
ing coronary artery bypass graft surgery or with trauma or
myocarditis. It has been uncertain whether a similar amount
of damage in different settings has the same prognostic
implications. There have been different thresholds for iden-
tifying an infarct in trials undertaken up to this time in the
U.S.: CK-MB .2 times the upper limit of normal (ULN)
for spontaneous MI; CK-MB .3 times the ULN with
coronary artery interventions; and CK-MB .5 to 10 times
the ULN for bypass surgery. It is important that the
background for such choices be subjected to research and
verified or rejected from different databases. However, the
Joint ESC/ACC Expert Committee reached the consensus
opinion that, irrespective of the clinical circumstances (ex-
cept for coronary artery surgery or intended myocardial
lesions such as radiofrequency ablation of arrhythmias or
septal ablation for hypertrophic cardiomyopathy), the same
discriminative value for each biochemical marker should be
applied, as they reflect the same amount of myocardial necrosis.
In clinical trials, as in clinical practice, measurement of
cardiac troponin T or I is preferred over measurement of
CK-MB, as well as total CK and other biomarkers, for the
diagnosis of MI. Assessment of the quantity of myocardial
damage (infarct size) is also an important trial end point.
The use of cardiac troponin will undoubtedly increase the
number of events recorded in a particular trial because of its
increased sensitivity for detecting MI. Ideally, data should
be presented so that trialists can translate the MI end point
chosen in one trial into the end point of another trial. Thus,
measurements should be presented in a continuous manner
(distribution) to allow independent judgment of the clinical
end points.
In the design of a trial, investigators should specify the
expected effect of the new treatment under investigation.
Factors that must be considered include:
1) Reduction in the incidence of spontaneous myocardial
damage (events) in treated patients versus control sub-
jects.
2) Reduction in the incidence of angioplasty- or bypass
surgery–induced myocardial damage.
3) Reduction in the amount of myocardial damage (infarct
size) under any circumstance. Analysis of the actual
distribution of infarct sizes observed (area under the
curve of a biomarker or peak values) is more appropriate
than analysis of the presence or absence of events only.
VI. IMPLICATIONS OF MI IN THE EVOLUTION OF
CORONARY DISEASE IN AN INDIVIDUAL PATIENT
Until recently, MI was recognized as a major event, often
fatal, and with major implications for survivors. This para-
Figure 2. Timing of release of various biomarkers following acute, isch-
emic myocardial infarction.
Peak A, early release of myoglobin or CK-MB isoforms after AMI;
peak B, cardiac troponin after AMI; peak C, CK-MB after AMI; peak D,
cardiac troponin after unstable angina. Data are plotted on a relative scale,
where 1.0 is set at the AMI cutoff concentration.
AMI 5 acute myocardial infarction; CAD 5 coronary artery disease;
CK 5 creatine kinase.
Reproduced with permission, WU AH, et al. Clin Chem 1999;45:
1104–1121.
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digm has changed as a result of better management strate-
gies for patients with coronary artery disease, as well as
better methods for detecting or excluding myocardial ne-
crosis. The introduction of techniques for measuring cardiac
troponin allows for very sensitive and very specific detection
of minimal quantities of myocardial necrosis. This new
technology serves as the cornerstone of the new definition of
MI outlined in this document. It is appreciated that this
new definition will attach the label of MI to more patients.
Similarly, it will identify more infarcts and more episodes of
reinfarction in patients with progressive coronary artery
disease. This change in the definition of MI seems reason-
able, because it has been definitively shown that any amount
of myocardial damage, as detected by cardiac troponins,
implies a worsened long-term outcome for the patient. This
appears to be true both for spontaneous events and for
events associated with coronary procedures. Currently avail-
able analyses demonstrate no threshold below which eleva-
tions of troponins are harmless and without negative impli-
cations for prognosis. Thus, any other definition of MI
would involve an arbitrary setting of limits for an abnormal
troponin and would be open to criticism and considerable
debate. It should be emphasized that there is continuity
from “minimal myocardial damage,” characterized by eleva-
tion of cardiac troponin without apparent elevation of other
biomarkers (also termed “infarctlet” or “necrosette”), to the
classic “large myocardial infarction,” often complicated by
heart failure, shock or life-threatening arrhythmia. In ap-
plying the proposed new diagnostic criteria to clinical
practice, patients should not be labeled primarily as “myo-
cardial infarction” but rather as patients with coronary artery
disease with MI. In addition, it is essential that other
descriptors of the patient’s cardiac status be included, such
as current left ventricular function, the extent and severity of
coronary artery lesions and an estimate of the evolution of
the disease over recent months (i.e., stable or unstable). The
crucial elements in this descriptive process can be obtained
from invasive diagnostic studies, but may also be reliably
estimated from a number of noninvasive studies.
Patients who undergo coronary artery revascularization
(coronary angioplasty or bypass surgery) are at risk for
myocardial damage, or rather MI according to the new
definition. These risks have always been present in the
setting of coronary artery interventions, but they have been
highlighted by the new, more sensitive biomarkers. Detec-
tion of a very small myocardial infarct in this setting augurs
a worse prognosis for the patient, rather than if biomarkers
had been normal. However, it should be appreciated that
long-term patient outcome and prognosis may be improved
significantly by the revascularization procedure. For exam-
ple, a patient with unstable angina and severe left anterior
descending coronary artery stenosis will benefit from coro-
nary artery stenting, despite a small elevation in blood
troponin levels. The benefit far outweighs the negative
impact of the small, procedure-related infarct. It goes
without saying that every measure should be taken to
prevent even such small infarcts in the setting of coronary
artery interventional procedures.
VII. SOCIAL AND PUBLIC POLICY
IMPLICATIONS OF REDEFINING MI
Modification of the definition of a specific diagnosis such as
MI has a number of implications for individual citizens as
well as for society. The process of assigning a specific
diagnosis to a patient should be associated with a specific
value to the patient. The resources spent on recording and
tracking a particular diagnosis must also have a specific value
to society to justify the effort. A tentative or final diagnosis
is the basis for advice about further diagnostic testing,
treatment, life-style changes and prognosis for the patient.
The aggregate of patients with a particular diagnosis is the
basis for health care planning and policy and resource
allocation.
One of the goals of good clinical practice is to reach a
definitive and specific diagnosis that is supported by current
scientific knowledge. The approach to the definition of MI
outlined in this document meets this goal. In general, the
conceptual meaning of the term “acute MI” has not
changed, although new sensitive diagnostic methods have
been developed to diagnose this entity. Thus, the current
diagnosis of acute MI is a clinical diagnosis based on patient
symptoms, ECG changes and highly sensitive biochemical
markers, as well as information gleaned from various imag-
ing techniques. However, it is important to characterize the
extent of the patient’s myocardial injury and residual left
ventricular function, as well as the severity of coronary artery
disease, rather than merely making a diagnosis of MI.
Many patients with coronary artery thrombosis leading to
MI die suddenly. Difficulties in the definitions of sudden
and out-of-hospital death make attribution of the cause of
death variable among physicians, regions and countries. For
example, out-of-hospital death is generally ascribed to
ischemic heart disease in the U.S. but to stroke in Japan.
These arbitrary and cultural criteria need reexamination.
It is important that any revised criteria for the definition
of MI involve comparability of this definition over time so
that adequate trend data can be obtained. Furthermore, it is
essential to ensure widespread availability and standard
application of measures generating these criteria to ensure
comparability of data from various geographic regions.
Shifts in criteria resulting in substantial increases or de-
creases in case identification will have significant health
resource and cost implications. Moreover, an increase in
sensitivity of the criteria for acute MI might entail negative
consequences for some patients who are not currently
labeled as having had an MI. In contrast, increasing
diagnostic sensitivity for MI can have a positive impact on
society:
c Increasing the sensitivity of diagnostic criteria for MI will
result in more cases identified, thereby allowing appro-
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priate secondary prevention and hopefully reduced health
care costs in the future,
c Increasing the specificity of diagnostic criteria for MI will
result in elimination of noncases, thereby leading to
reduced costs for hospital stays and secondary prevention.
Finally, it should be appreciated that the proposed mod-
ification of the definition of MI may be associated with
consequences for the patient with respect to psychological
status, life insurance, professional career, as well as driving
and pilot licenses. The diagnosis is associated with societal
implications as well: diagnosis-related grouping (DRG),
hospital reimbursement, mortality statistics, sick leave and
disability applications and clinical guideline preparation will
all be affected.
To meet this challenge, physicians must be adequately
informed of the changing diagnostic criteria. Educational
materials will need to be created, and treatment guidelines
must be appropriately adapted. Professional societies, par-
ticularly the ACC, the American Heart Association and the
ESC, should take steps to facilitate the rapid dissemination
of the revised definition to physicians, other health care
professionals, administrators and the general public.
SUMMARY
Definition of MI. Criteria for acute, evolving or recent MI.
Either one of the following criteria satisfies the diagnosis for
an acute, evolving or recent MI:
1) Typical rise and gradual fall (troponin) or more rapid rise
and fall (CK-MB) of biochemical markers of myocardial
necrosis with at least one of the following:
a) ischemic symptoms;
b) development of pathologic Q waves on the ECG;
c) ECG changes indicative of ischemia (ST segment
elevation or depression); or
d) coronary artery intervention (e.g., coronary angio-
plasty).
2) Pathologic findings of an acute MI.
Criteria for established MI.
Any one of the following criteria satisfies the diagnosis
for established MI:
1) Development of new pathologic Q waves on serial
ECGs. The patient may or may not remember previous
symptoms. Biochemical markers of myocardial necrosis
may have normalized, depending on the length of time
that has passed since the infarct developed.
2) Pathologic findings of a healed or healing MI.
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